Gilead's Results Boosted by Hepatitis Drug

Gilead Sciences reported nearly $2.3 billion in first-quarter sales for its new hepatitis C treatment Sovaldi in what is believed to be the best-selling prescription drug launch in history.



from WSJ.com: US Business http://ift.tt/1jGFFYl

via IFTTT